CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,255 | -19.2% | 270 | 0.0% | 0.00% | – |
| Q2 2023 | $15,158 | +24.1% | 270 | 0.0% | 0.00% | – |
| Q1 2023 | $12,212 | +5.4% | 270 | -5.3% | 0.00% | – |
| Q4 2022 | $11,586 | -39.0% | 285 | -1.7% | 0.00% | – |
| Q3 2022 | $19,000 | +11.8% | 290 | 0.0% | 0.00% | – |
| Q2 2022 | $17,000 | -5.6% | 290 | 0.0% | 0.00% | – |
| Q1 2022 | $18,000 | -18.2% | 290 | 0.0% | 0.00% | – |
| Q4 2021 | $22,000 | -31.2% | 290 | 0.0% | 0.00% | – |
| Q3 2021 | $32,000 | -56.2% | 290 | -35.6% | 0.00% | -100.0% |
| Q2 2021 | $73,000 | +108.6% | 450 | +55.2% | 0.00% | – |
| Q1 2021 | $35,000 | -20.5% | 290 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $44,000 | +158.8% | 290 | +45.0% | 0.00% | – |
| Q3 2020 | $17,000 | +13.3% | 200 | 0.0% | 0.00% | – |
| Q2 2020 | $15,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |